HIV patients to keep receiving promising treatments in new study

NCT ID NCT07393659

Recruiting now Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study offers continued access to HIV medications (fostemsavir or dolutegravir/lamivudine) for 183 people who completed earlier ViiV Healthcare studies and are still benefiting. The goal is to provide treatment while collecting more safety information. Participants must have a doctor confirm they still need the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fostemsavir and Dolutegravir/Lamivudine combination
What this could lead to: If successful, this study helps ensure uninterrupted access to effective HIV treatment for people who need it.
What could go wrong: This is an open-label study without a placebo, so results may be less reliable. It only includes people already benefiting, which may not reflect broader outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Durban, KwaZulu-Natal, 4013, South Africa
GSK Investigational Site
RECRUITING

Jouberton, Matlosana, 2571, South Africa
GSK Investigational Site
RECRUITING

Gauteng, 1864, South Africa
GSK Investigational Site
RECRUITING

Johannesburg, 2112, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.